Head & Neck Cancer Awareness Month - NRG Head and Neck Cancer Portfolio

April 15 2025

NRG Oncology has multiple active trials currently available to patients with head and neck cancer. All active NRG Oncology clinical trials can be found on our website protocol search page.

NRG-CC013

Status: Temporarily closed to accrual

Study Name: A Randomized, Masked, Placebo Controlled, Phase II Trial Of Concurrent Chemoradiation With BMX-001 In Patients With Head And Neck Squamous Cell Carcinoma Receiving Concurrent Chemoradiation

Trial Webpage | Patient Study Webpage | Patient Study Brochure

NRG-HN006

Status: Temporarily closed to accrual

Study Name: Randomized Phase II/III Trial Of Sentinel Lymph Node Biopsy Versus Elective Neck Dissection For Early-Stage Oral Cavity Cancer

Trial Webpage | Patient Study Webpage | Patient Study Brochure

NRG-HN009

Status: Open to accrual

Study Name: Randomized Phase II/III Trial of Radiation with High-Dose Cisplatin (100 mg/m2) Every Three Weeks versus Radiation with Low-Dose Weekly Cisplatin (40 mg/m2) for Patients with Locoregionally Advanced Squamous Cell Carcinoma of The Head And Neck (SCCHN)

Trial Webpage | Patient Study Webpage | Patient Study Brochure

NRG-HN010

Status: Open to accrual

Study Name: A Controlled, Randomized Phase II Trial of Docetaxel Plus Trastuzumab Versus Ado-Trastuzumab Emtansine for Recurrent, Metastatic, or Treatment-Naïve, Unresectable Her2-Positive Salivary Gland Cancer

Trial Webpage | Patient Study Webpage | Patient Study Brochure

NRG-HN011

Status: Open to accrual

Study Name: A Randomized Phase II Study of Nivolumab versus Nivolumab and BMS-986016 (Relatlimab) as Maintenance Treatment after First-line Treatment with Platinum-Gemcitabine-Nivolumab for Patients with Epstein-Barr Virus-Associated Recurrent/Metastatic Nasopharyngeal Carcinoma (REMAIN)

Trial Webpage  | Patient Study Webpage  |  Patient Study Brochure

NRG-HN014

Status: Open to accrual

Study Name: Randomized Phase III Trial of Neoadjuvant Immunotherapy With Response-Adapted Treatment Versus Standard-of-Care Treatment for Resectable Stage III/IV Cutaneous Squamous Cell Carcinoma

Trial Webpage  | Patient Study Webpage  | Patient Study Brochure

NRG-RTOG 1216

Status: Open to accrual

Study Name: Randomized Phase II/III Trial of Adjuvant Radiation Therapy with Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck

Trial Webpage

Stay current with science. Sign up for our newsletter.

Support NRG Oncology.
Help Our Cause.

We are a leading protocol organizations within the National Clinical Trials Network and we seek to improve the lives of cancer patients by conducting practice-changing, multi-institutional clinical and translational research. Learn More

Donate Today

NRG Oncology Foundation, Inc, is a nonprofit, tax-exempt foundation. Donations to NRG Oncology help us conduct this important mission, and are tax-deductible to the extent permitted by law.